Gold.com (NYSE:GOLD – Get Free Report) and Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) are both small-cap industrials companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
Volatility and Risk
Gold.com has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -1.52, meaning that its share price is 252% less volatile than the S&P 500.
Profitability
This table compares Gold.com and Capstone Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gold.com | 0.35% | 17.82% | 4.21% |
| Capstone Therapeutics | -41.26% | -114.15% | -39.74% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gold.com | $10.98 billion | 0.11 | $17.32 million | $2.92 | 14.87 |
| Capstone Therapeutics | $48.11 million | 0.10 | -$21.23 million | ($3.37) | -0.09 |
Gold.com has higher revenue and earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than Gold.com, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for Gold.com and Capstone Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gold.com | 0 | 2 | 4 | 0 | 2.67 |
| Capstone Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Gold.com currently has a consensus price target of $59.75, indicating a potential upside of 37.59%. Given Gold.com’s stronger consensus rating and higher possible upside, research analysts plainly believe Gold.com is more favorable than Capstone Therapeutics.
Institutional and Insider Ownership
62.9% of Gold.com shares are owned by institutional investors. Comparatively, 2.5% of Capstone Therapeutics shares are owned by institutional investors. 23.1% of Gold.com shares are owned by company insiders. Comparatively, 39.3% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Gold.com beats Capstone Therapeutics on 13 of the 14 factors compared between the two stocks.
About Gold.com
A-Mark Precious Metals, Inc., together with its subsidiaries, operates as a precious metals trading company. It operates in three segments: Wholesale Sales & Ancillary Services, Direct-to-Consumer, and Secured Lending. The Wholesale Sales & Ancillary Services segment sells gold, silver, platinum, and palladium in the form of bars, plates, powders, wafers, grains, ingots, and coins. This segment also offers various ancillary services, including financing, storage, consignment, logistics, and various customized financial programs; and designs and produces minted silver products. The Direct-to-Consumer segment provides access to an array of gold, silver, copper, platinum, and palladium products through its websites and marketplaces. It operates five company-owned websites targeting specific niches within the precious metals retail market. This segment also operates as a direct retailer of precious metals to the investor community and markets its precious metal products on television, radio, and the internet, as well as through customer service outreach. The Secured Lending segment originates and acquires commercial loans secured by bullion and numismatic coins; and serves coin and precious metal dealers, investors, and collectors. The company serves customers, including financial institutions, bullion retailers, industrial manufacturers and fabricators, sovereign mints, refiners, coin and metal dealers, investors, collectors, and e-commerce and other retail customers. It has operations in the United States, rest of North America, Europe, the Asia Pacific, Africa, and Australia. A-Mark Precious Metals, Inc. was founded in 1965 and is headquartered in El Segundo, California.
About Capstone Therapeutics
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Receive News & Ratings for Gold.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gold.com and related companies with MarketBeat.com's FREE daily email newsletter.
